This is significantly higher than most available weight-management medications
States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all
Some analyses from these trials showed modest reductions in inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP)
Australia's Chief Medical Officer and the medicines regulator, the Therapeutic Goods Administration, have warned Australians not to take unapproved peptides, saying they were often poorly labelled and presented a health risk
A trial is not the same as receiving a prescribed medicine
They also include different formulations, delivery devices, and combinations with other drugs